MYASTHENIA GRAVIS: REPORT OF CASE RECEIVING UNUSUAL DOSAGE OF NEOSTIGMINE
Authors: J A RIDER, W H PICKETT, A W HARRISON
Journal: Annals of Internal Medicine (1951)

Case Reports1 August 1951MYASTHENIA GRAVIS: REPORT OF CASE RECEIVING UNUSUAL DOSAGE OF NEOSTIGMINEJ. A. RIDER, M.D., W. H. PICKETT, M.D., A. W. HARRISON, M.D.J. A. RIDER, M.D.Search for more papers by this author, W. H. PICKETT, M.D.Search for more papers by this author, A. W. HARRISON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-35-2-463 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONMyasthenia gravis, an endocrine or metabolic disease characterized by excessive fatigability of skeletal muscle, eluded all attempts at treatment until Edgeworth1in 1930 found that ephedrine was beneficial. Then Walker2in 1935 introduced neostigmine, which has remained the best and most commonly used therapeutic agent to date. Recently Cholinesterase inhibitors have been used with varying promise. Among these have been "DFP," diisopropyl fluorophosphate used by Comroe,3"HETP," hexaethyltetraphosphate, employed by Westerberg,4and "TEPP," tetraethylpyrophosphate, first tried clinically by Burgen.5Surgical approach began in 1913, when Sauerbruch6employed thymectomy, but it remained for Blalock7in 1939 to perform the first...Bibliography1. Edgeworth H: A report on progress on the use of ephedrine in a case of myasthenia gravis, J. A. M. A. 94: 1136, 1930. CrossrefGoogle Scholar2. Walker MB: Case showing the effect of prostigmine on myasthenia gravis, Proc. Roy. Soc. Med. 28: 759-761, 1935. CrossrefMedlineGoogle Scholar3. ComroeToddGammonLeopoldKoelleBodanskyGilman JHJGDIHGBOA: The effect of di-isopropyl-fluoro-phosphate (DFP) upon patients with myasthenia gravis, Am. J. M. Sc. 212: 641-651, 1946. CrossrefMedlineGoogle Scholar4. WesterbergLuros MRJT: The clinical use of hexaethyl tetraphosphate in myasthenia gravis, Univ. Hosp. Bull., Ann Arbor 14: 15-17, 1948. MedlineGoogle Scholar5. BurgenKeelMcAlpine ASCAD: Tetra-ethylpyrophosphate in myasthenia gravis, Lancet 1: 519-521, 1948. CrossrefMedlineGoogle Scholar6. Sauerbruch R Cited by Schumacher, Roth: Thymektomie bei einem Fall von Morbus Basedowi mit Myasthenie, Mitt. a. d. Grenzgeb. d. Med. u. Chir. 25: 746, 1913. Google Scholar7. BlalockMasonMorganRiven AMFHJSS: Myasthenia gravis and tumors of the thymic region, Ann. Surg. 110: 544-561, 1939. CrossrefMedlineGoogle Scholar8. Blalock A: Thymectomy in the treatment of myasthenia gravis; 20 cases, J. Thoracic Surg. 13: 316-339, 1944. CrossrefGoogle Scholar9. Keynes G: Surgery of the thymus gland, Brit. J. Surg. 33: 201-214, 1946. CrossrefMedlineGoogle Scholar10. ClagettEaton OTLM: Surgical treatment of myasthenia gravis, J. Thoracic Surg. 16: 62-80, 1947. CrossrefGoogle Scholar11. Viets HR: Myasthenia gravis, J. A. M. A. 127: 1089-1096, 1945. CrossrefGoogle Scholar12. AdamsAllan RFN: Thymectomy in the treatment of myasthenia gravis, Dis. of Chest 13: 436-452, 1947. CrossrefMedlineGoogle Scholar13. Viets HR: Myasthenia gravis treated with large doses of neostigmine methylsulfate, intramuscularly and intravenously, and with neostigmine bromide orally, Am. J. M. Sc. 208:701-708, 1944. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication June 28, 1949.From the Departments of Internal Medicine and Surgery, The University of Texas Medical Branch, Galveston, Texas. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBreaking Down Myasthenic CrisisFirst Descriptions of Clinical SyndromesMyasthenia Gravis 1 August 1951Volume 35, Issue 2Page: 463-468KeywordsCholinesterase inhibitorsMetabolic disordersMyasthenia gravisSkeletal musclesSurgeryThymectomy ePublished: 1 December 2008 Issue Published: 1 August 1951 PDF downloadLoading ...